Shares of Sakar Healthcare surged 10.5% to ₹1,120 on September 7 after the company announced it had secured 14 oncology product approvals across the EU, UK, and Canada — a haul that extends a blistering run from ₹863.35 just a week ago, representing a cumulative gain of roughly 30% in five trading sessions. Sakar Healthcare's 14 Cancer-Drug Approvals Ignited a 30% Rally in One Week — Can a Tiny Indian Manufacturer Sustain This Breakout Valuation?
Shares rocketed as Sakar Healthcare, a small Gujarat-based drugmaker with a market cap around ₹2,400 crore, secured 14 new oncology product approvals across the EU, UK, and Canada in a single filing — a regulatory haul almost unheard of for a company with trailing revenue of just ₹204 crore. The stock has surged roughly 30% in five sessions, from ₹863 to ₹1,120, blowing past its prior 52-week high. Investors are betting this marks Sakar's transformation from a domestic contract manufacturer into a regulated-market cancer-drug exporter. The question is whether the numbers can keep up with the narrative.
• Fourteen Approvals in One Shot Signals the Pipeline Is Finally Turning Into Revenue. Sakar disclosed on September 1 that 14 oncology products were approved, with lead partner Accord Healthcare receiving five EMA site-variation clearances, bringing its total to six of eight planned technology transfers.
Additional partners in the UK and Germany won three more product approvals, while six of Sakar's own licensed-out drugs received marketing authorizations — four in the EU, one each in the UK and Canada. Each approval unlocks a new revenue stream from high-margin regulated markets.
• The Accord Partnership Is the Real Engine — and It's Still Ramping. Imatinib was the first of nine oncology products Accord plans to transfer to Sakar's manufacturing site , and now six of those transfers are approved. Accord ranks among the top three oncology companies in most EU markets with operations in over 45 countries. Piggybacking on an established distributor lets Sakar skip the costliest part of going global — building its own sales force.
• The Factory Has Room to Grow, but Revenue Must Catch Up to the Valuation. Sakar's facility can generate substantially more revenue by operating three shifts at roughly 80% utilization — currently at just 8% — without major new capital spending. Management has reiterated an aspirational ₹500 crore revenue target by FY28.
Analysts expect the oncology business alone to grow at a compound rate of about 118% annually to ₹350 crore between FY25 and FY28. Yet the stock already trades at roughly 60 times earnings on a P/E basis — with a P/E ratio of 59.54 as of early September — leaving little room for execution stumbles.
• Volatility Is Extreme and Liquidity Is Thin. The share price has been volatile over the past three months, moving more than 75% of Indian stocks, with typical weekly swings of 7.4%.
Over three years, earnings per share grew roughly 2% annually while the stock climbed 20% per year — a gap that demands the oncology ramp-up deliver real profit growth, fast, or investors face a painful correction.